Form 4: Neurocrine Biosciences CFO Matt Abernethy Reports Stock Transactions

Matt Abernethy, CFO of Neurocrine Biosciences, reports the acquisition and disposal of common stock and restricted stock units on January 31, 2025, according to a pre-arranged Rule 10b5-1 trading plan.

Summary

• On January 31, 2025, Matt Abernethy, the Chief Financial Officer of Neurocrine Biosciences, engaged in transactions involving the company's stock.
• These transactions included the acquisition of 2,436 shares of common stock and the disposal of 1,283 shares at a weighted average price of $152.8728 per share.
• The transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 1, 2022.
• Abernethy also reported owning 32,681 shares of common stock following the reported transactions.
• Additionally, 2,436 Restricted Stock Units (RSUs) vested on January 31, 2025, with each RSU representing a contingent right to receive one share of Neurocrine Biosciences' common stock.
• The reporting person now owns 2,437 Restricted Stock Units.

Sentiment

Score: 5

Explanation: This Form 4 filing is a routine disclosure of insider transactions. The use of a 10b5-1 plan suggests a pre-planned strategy, making the sentiment neutral.

Industry Context

Form 4 filings are a routine part of the regulatory landscape for publicly traded companies, providing transparency into the transactions of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.

Comparison to Industry Standards

• Comparing Abernethy's transactions to those of other CFOs in similarly sized biotech companies would provide context.
• For example, if the CFO of Amgen or Biogen were to execute similar transactions, the market reaction and interpretation might be different due to the size and maturity of those companies.
• The use of a 10b5-1 plan is a common practice to avoid accusations of insider trading, aligning with industry best practices for executives.

Stakeholder Impact

• Shareholders may interpret these transactions as part of the executive's personal financial planning.
• The transactions are unlikely to have a significant impact on employees, customers, suppliers, or creditors.

Key Dates

Keywords

Neurocrine Biosciences, NBIX, Matt Abernethy, CFO, Form 4, Stock Transactions, Rule 10b5-1, Restricted Stock Units, Common Stock, Insider Trading